Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrthoLogic to start phase III fracture repair trial:

This article was originally published in Clinica

Executive Summary

The US FDA has given OrthoLogic the go-ahead to begin a phase III clinical trial of its injectable synthetic peptide product, Chrysalin, for accelerating fracture repair. The trial is scheduled to begin enrolling around 500 patients from 25 to 30 medical centres this autumn. The enrolment process is expected to take approximately 24 months, with a six-month follow-up period. OrthoLogic, of Tempe, Arizona, has obtained the worldwide rights to use Chrysalin for all orthopaedic indications through a series of agreements with Galveston, Texas-based Chrysalis BioTechnology. Chrysalin's application for spinal fusion and articular cartilage defect repair is also being explored.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel